Clinical trials
Biliary Tract Cancer clinical trials
Below are recruiting biliary tract cancer clinical trials, each written for real people, not researchers. We’re tracking 129 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06749730RecruitingPhase 2
Study of four drugs for advanced bile duct cancer
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
ZhengzhouAges 18–80 - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT06792435RecruitingPhase 1/Phase 2
Study of XNW27011 for advanced solid tumors that failed standard therapy
This trial tests an investigational drug called XNW27011 for people with advanced solid tumors that have not responded to standard therapies. It may be especially relevant for tumors that have a specific protein called CLDN18.2, but it is not required for the first part of the study.
Jinan, ShandongAges 18 years+ - NCT06793709Recruiting
Study of Tasfygo for bile duct cancer with FGFR2 gene change
This study is watching people with a certain type of bile duct cancer that has a specific gene change (FGFR2 fusion). It looks at what happens when they take the drug Tasfygo after their cancer did not respond to chemotherapy.
TokyoAges Any age - NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06909188Recruiting
Helicobacter infection in bile duct cancer patients
This study looks for links between Helicobacter bacteria and cancers of the bile ducts and gallbladder. It compares patients with bile duct cancer, people having gallbladder surgery for non-cancer reasons, and healthy liver donors.
New Delhi, National Capital Territory of DelhiAges 18 years+ - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT06938321RecruitingPhase 1/Phase 2
New drug combo for advanced bile duct and gallbladder cancer
This trial tests two new drugs, AK130 and AK112, for people with advanced bile duct or gallbladder cancer that has stopped responding to standard chemotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06978114RecruitingPhase 2
Study of a new drug for advanced bile duct cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy for people with advanced bile duct cancer. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06988592Recruiting
Chemo plus immunotherapy for advanced bile duct cancer
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07025174RecruitingPhase 2
Sequential anti-angiogenic therapy after immunotherapy for advanced bile duct cancer
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
Hangzhou, ZhejiangAges 18–75 - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT07107750RecruitingPhase 1
New drug combo for untreated advanced bile duct cancer
This trial tests a new targeted drug (emavusertib) combined with standard chemotherapy and immunotherapy for people with advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination is safe and effective.
St Louis, MissouriAges 18 years+ - NCT07135544RecruitingPhase 2
Adebrelimab plus apatinib and chemo for new bile duct cancer
This study tests a combination of three medicines (adebrelimab, apatinib, and standard chemotherapy) for people with newly diagnosed bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if the combination can shrink the tumor and make it possible to remove later.
Wuhan, HubeiAges 18–80 - NCT07146646RecruitingPhase 2
Chemo combo for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Cleveland, OhioAges 19 years+ - NCT07151118Recruiting
Blood test for advanced biliary tract cancer
This study uses a simple blood test (ctDNA) to learn more about the genetic makeup of advanced biliary tract cancers. It may help researchers understand how these cancers respond to treatment, and it doesn't involve any extra drugs or procedures—just blood draws.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07156058Recruiting
Personalized therapy after surgery for bile duct cancer
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
BeijingAges 18 years+ - NCT07159204RecruitingPhase 2
A trial testing a chemo plus immunotherapy combo for biliary tract cancer
This trial tests a combination of a special form of chemotherapy (paclitaxel micelle) and an immunotherapy for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder) that has not responded to or stopped working after first treatment. The goal is to see if this combination can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07176962Recruiting
Blood test for early detection of bile duct cancer
This study is testing a new blood test that looks for signs of DNA changes linked to biliary tract cancer. It aims to see if the test can find these cancers early. If you have biliary tract cancer or a high suspicion of it, you may be able to help.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07206355Recruiting
Studying bile duct and liver lesions for new cancer tests
This study looks at tissue samples from people with bile duct, liver, or pancreas problems to develop better ways to detect cancers in these areas. If you are scheduled for a biopsy, scan, or surgery for a suspected growth in your liver, pancreas, or bile duct, you may be able to help.
NottinghamAges 16 years+ - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for biliary tract cancer?
- Yes. Clin2 currently lists 129 recruiting biliary tract cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a biliary tract cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a biliary tract cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.